Last Updated: November 16, 2026

Investigational Drug Information for apabetalone

« Back to Dashboard


What is the development status for investigational drug apabetalone?

apabetalone is an investigational drug.

There have been 9 clinical trials for apabetalone. The most recent clinical trial was a Phase 3 trial, which was initiated on April 15th 2025.

The most common disease conditions in clinical trials are Familial Primary Pulmonary Hypertension, Atherosclerosis, and Myocardial Ischemia. The leading clinical trial sponsors are Resverlogix Corp, ICON plc, and Medidata Solutions.

There are two hundred and forty-one US patents protecting this investigational drug and three hundred and fifty international patents.

Recent Clinical Trials for apabetalone
TitleSponsorPhase
A Study of Apabetalone in Subjects With Long -COVIDResverlogix CorpPHASE2
Apabetalone for Pulmonary Arterial HypertensionCanadian Institutes of Health Research (CIHR)Phase 2
Apabetalone for Pulmonary Arterial HypertensionResverlogix CorpPhase 2

See all apabetalone clinical trials

Clinical Trial Summary for apabetalone

Top disease conditions for apabetalone
Top clinical trial sponsors for apabetalone

See all apabetalone clinical trials

US Patents for apabetalone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
apabetalone ⤷  Start Trial Pharmaceutical compositions for substituted quinazolinones Resverlogix Corp. (Calgary, Alberta, CA) ⤷  Start Trial
apabetalone ⤷  Start Trial Compositions and therapeutic methods for the treatment of complement-associated diseases Resverlogix Corp. (Calgary, Alberta, CA) ⤷  Start Trial
apabetalone ⤷  Start Trial Anti-inflammatory agents Resverlogix Corp. (Calgary, Alberta, CA) ⤷  Start Trial
apabetalone ⤷  Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Start Trial
apabetalone ⤷  Start Trial Chemokine receptor modulators and uses thereof FLX Bio, Inc. (South San Francisco, CA) ⤷  Start Trial
apabetalone ⤷  Start Trial Therapy for promoting cell growth MOLEAC PTE. LTD. (Singapore, SG) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for apabetalone

Drugname Country Document Number Estimated Expiration Related US Patent
apabetalone Australia AU2012330885 2031-11-01 ⤷  Start Trial
apabetalone Canada CA2851996 2031-11-01 ⤷  Start Trial
apabetalone China CN103945848 2031-11-01 ⤷  Start Trial
apabetalone Denmark DK2773354 2031-11-01 ⤷  Start Trial
apabetalone European Patent Office EP2773354 2031-11-01 ⤷  Start Trial
apabetalone Spain ES2745471 2031-11-01 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Apabetalone Development Update and Market Projection

Last updated: September 3, 2026

Apabetalone, also known as RVX-208, is an oral, selective bromodomain and extraterminal domain (BET) inhibitor developed by Resverlogix Corp. for cardiovascular, renal, and inflammatory diseases. The drug has no FDA, EMA, or Health Canada marketing approval. Its pivotal BETonMACE trial did not meet the primary major adverse cardiovascular event endpoint, leaving apabetalone without a validated registration pathway or near-term commercial revenue base.

The asset retains potential in selected high-risk populations, particularly patients with type 2 diabetes, chronic kidney disease, and cardiovascular disease. That potential depends on a new, adequately powered clinical program and a narrower indication than the original broad cardiovascular strategy.

What is apabetalone and how does it work?

Apabetalone is a small-molecule BET inhibitor that preferentially targets the second bromodomain of BET proteins, including BRD2, BRD3, and BRD4. BET proteins regulate gene transcription linked to inflammation, lipid metabolism, thrombosis, fibrosis, and vascular disease.

The development rationale has focused on several mechanisms:

  • Reduction of inflammatory gene expression
  • Modulation of hepatic lipid and apolipoprotein production
  • Suppression of vascular inflammation
  • Potential reduction of fibrosis and renal disease progression
  • Effects on macrophage activation and atherosclerotic plaque biology

Apabetalone is differentiated from PCSK9 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists because it targets epigenetic transcription rather than LDL receptor recycling, glucose excretion, weight regulation, or aldosterone signaling.

What is the current development status of apabetalone?

Apabetalone remains an investigational drug. The pivotal BETonMACE Phase 3 study was completed, but the primary efficacy endpoint was not statistically significant.

Development milestone Status
Drug candidate Apabetalone, RVX-208
Developer Resverlogix Corp.
Modality Oral small-molecule BET inhibitor
Lead cardiovascular program Type 2 diabetes, low HDL cholesterol, recent acute coronary syndrome
Pivotal trial BETonMACE, Phase 3
Enrollment Approximately 2,400 patients
Primary endpoint Three-point MACE
Primary result Not statistically significant
FDA approval None
EMA approval None
Orange Book listing None
Biosimilar status Not applicable
Commercial sales None from an approved product

BETonMACE randomized 2,425 patients with type 2 diabetes, low HDL cholesterol, and a recent acute coronary syndrome to apabetalone or placebo. The study did not meet its primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The reported hazard ratio was approximately 0.82, with a p-value above the prespecified significance threshold (Nicholls et al., 2021).

The trial generated potentially relevant secondary findings, including lower rates of hospitalization for heart failure and signals in patients with chronic kidney disease. Those findings are hypothesis-generating rather than registration-enabling because the study was not powered to establish those outcomes as standalone approval endpoints.

What were the results of the BETonMACE Phase 3 trial?

BETonMACE was the central validation test for apabetalone in cardiovascular disease. Its failure materially reduced the probability of a broad cardiovascular indication.

BETonMACE element Reported outcome
Population Type 2 diabetes, low HDL cholesterol, recent ACS
Sample size 2,425 patients
Treatment Apabetalone 100 mg twice daily versus placebo
Follow-up Approximately 26 months median
Primary endpoint MACE
Primary result HR approximately 0.82
Statistical result p approximately 0.11
Heart-failure hospitalization Favorable signal
Renal subgroup Favorable signal in selected analyses
Regulatory consequence No approval filing based on the trial

The failure was not a clean demonstration of no biological activity. It was a failure to establish a statistically significant reduction in the prespecified primary endpoint. That distinction matters commercially, but it does not remove the need for a new confirmatory trial.

The strongest remaining clinical thesis is a targeted indication involving cardiorenal risk, rather than a general secondary-prevention cardiovascular label.

What diseases could apabetalone treat?

Resverlogix has evaluated or discussed apabetalone in several disease areas.

Cardiovascular disease

The original cardiovascular strategy focused on reducing recurrent cardiovascular events in high-risk patients. BETonMACE did not support that broad claim.

Chronic kidney disease

CKD is the most commercially credible rescue opportunity. Post hoc and subgroup analyses suggested potential renal benefits, including lower rates of kidney-related events in patients with diabetes and CKD. A future program would need to define a renal endpoint, such as sustained estimated glomerular filtration rate decline, kidney failure, or a composite renal outcome.

Heart failure

The reduction in heart-failure hospitalization in BETonMACE created a possible development path. The commercial opportunity would be stronger if apabetalone demonstrated benefit in a defined heart-failure population not adequately addressed by SGLT2 inhibitors, finerenone, and guideline-directed therapy.

Inflammatory and fibrotic diseases

BET inhibition has been investigated in pulmonary hypertension, neurodegenerative disease, NASH, and other inflammatory disorders. These programs have not established a late-stage development path for apabetalone.

What regulatory status does apabetalone have?

Apabetalone has not received marketing authorization from the FDA, EMA, or other major regulators. The FDA has granted development-related designations to the program, including Breakthrough Therapy Designation for a cardiovascular risk population, according to Resverlogix public disclosures. That designation does not establish efficacy, approval eligibility, or market exclusivity.

Regulatory question Answer
Is apabetalone FDA approved? No
Is there an FDA-approved indication? No
Is apabetalone in the Orange Book? No approved product listing
Does it have FDA new chemical entity exclusivity? No active commercial exclusivity because no NDA approval exists
Has it received a Breakthrough Therapy designation? Yes, according to company disclosures
Can the designation support approval after BETonMACE? No; a successful registration-quality trial remains necessary

Breakthrough Therapy Designation can accelerate interaction with the FDA, but it does not replace the requirement for substantial evidence of effectiveness.

What patents protect apabetalone?

Apabetalone is protected, or has been protected, by patent families covering BET inhibitors, chemical compounds, pharmaceutical compositions, and therapeutic uses. Resverlogix and related entities have been associated with patent filings for bromodomain inhibitors in the United States and internationally.

The commercially relevant categories are:

Patent category Potential scope
Composition of matter Apabetalone and structurally related BET inhibitors
Pharmaceutical composition Oral formulations and dosage forms
Method of treatment Cardiovascular, metabolic, renal, and inflammatory uses
Biomarker selection Patients defined by diabetes, HDL, CKD, or inflammatory risk
Combination therapy Use with lipid-lowering or cardiovascular medicines
Manufacturing Processes for producing active pharmaceutical ingredient and intermediates

The patent estate is less valuable than it would have been before the BETonMACE result because the regulatory value of broad cardiovascular claims has declined. Method-of-use patents tied to CKD or heart-failure outcomes could provide the most important remaining protection if a new indication is clinically validated.

No Orange Book patent listing exists because apabetalone has not been approved. Any future approved product would require a new FDA patent-listing analysis covering issued patents, patent-term adjustment, patent-term extension, and applicable statutory exclusivity.

When does apabetalone lose exclusivity?

There is no operative FDA market-exclusivity date because apabetalone has not been approved.

Patent expiry depends on the specific patent family, priority date, patent-term adjustment, terminal disclaimers, and jurisdiction. Broad early-filed composition patents are likely to face expiry pressure before a new product could complete another long cardiovascular or renal development program. Later patents directed to a defined patient population, formulation, dosing regimen, or biomarker could extend protection, but only if they are valid, enforceable, and commercially relevant.

Exclusivity type Current position
FDA NCE exclusivity Not started
FDA orphan exclusivity None identified
Pediatric exclusivity None identified
Orange Book patent exclusivity None
Composition patents Potentially limited by age of early filings
Later method-of-use patents Possible, subject to claim scope and validity
Generic blocking position No immediate FDA pathway because there is no approved reference product

A generic company cannot file an ANDA referencing an unapproved apabetalone product. If Resverlogix obtains approval, generic entry could occur through Paragraph IV litigation against listed patents or after patent and regulatory exclusivities expire.

Which companies are challenging apabetalone?

No active generic Paragraph IV challenge is expected because apabetalone has no FDA-approved reference product and no Orange Book listing. No biosimilar challenge applies because apabetalone is a small molecule, not a biologic.

The competitive threat is therefore clinical and commercial rather than immediate patent litigation. Potential competitors include:

  • SGLT2 inhibitors such as empagliflozin and dapagliflozin for cardiorenal protection
  • Finerenone for diabetic CKD
  • GLP-1 receptor agonists for diabetes, obesity, and cardiovascular risk reduction
  • PCSK9 inhibitors for intensive LDL lowering
  • Colchicine and anti-inflammatory cardiovascular strategies
  • Established heart-failure therapies, including ARNI products and beta blockers

Apabetalone would need to demonstrate incremental benefit on top of these treatments. A broad "add-on cardiovascular risk reduction" positioning would face a high evidence and reimbursement threshold.

What licensing deals affect apabetalone?

Resverlogix entered into a licensing arrangement with Shenzhen Hepalink Pharmaceutical Co. covering development and commercialization rights in Greater China. Public company disclosures described potential milestone payments, equity investment, and royalties, with total potential consideration reported at approximately $155 million.

The agreement is commercially important because China represents the most plausible external development and licensing market for an asset without a current Western regulatory pathway. Its economic value depends on whether Hepalink or another partner funds a new clinical program.

Licensing issue Commercial assessment
Territory Greater China under the reported agreement
Licensee Shenzhen Hepalink Pharmaceutical Co.
Consideration Upfront, equity, milestones, and royalties described in company disclosures
Maximum reported deal value Approximately $155 million
Current value driver Funding of new clinical development
Near-term product revenue None established

The transaction does not validate apabetalone clinically. It provides a potential regional development route and reduces the need for Resverlogix to finance all future studies independently.

How strong is the apabetalone patent estate?

The estate has moderate technical breadth but limited present commercial strength.

Composition-of-matter protection is generally the strongest form of pharmaceutical patent protection, but early priority dates can reduce the remaining term by the time of approval. Method-of-use patents could be more valuable for apabetalone because the post-BETonMACE strategy is likely to focus on CKD, heart failure, or a biomarker-defined group.

The estate faces four principal weaknesses:

  1. The lead Phase 3 trial failed its primary endpoint.
  2. The product has no regulatory exclusivity.
  3. A new indication may require years of clinical work.
  4. Competitors already have approved cardiorenal therapies.

The estate could improve if a new trial supports a narrow indication and generates patentable dosing, biomarker, combination, or patient-selection claims.

What market size could apabetalone reach?

Apabetalone has no current market because it is not approved. A realistic projection must therefore use scenario analysis rather than a conventional sales forecast.

Scenario Development outcome Commercial result
Downside No new pivotal program or failed confirmatory study No meaningful product revenue
Base case Regional partnering with limited development Licensing income possible; product sales remain negligible
Upside Positive CKD or heart-failure Phase 3 trial and approval Niche cardiorenal product with potential annual sales in the low hundreds of millions of dollars
High upside Broad label plus demonstrated benefit over standard therapy Larger opportunity, but low probability after BETonMACE

The addressable population is large, but the commercially reachable population would be much smaller. A label limited to high-risk diabetic CKD or heart-failure patients would likely target several hundred thousand treated patients in the United States and major European markets, not the entire diabetes or cardiovascular population.

A price comparable to specialty cardiovascular therapies could support meaningful revenue, but payer access would depend on outcome data, hospitalization reduction, renal preservation, and use alongside SGLT2 inhibitors and finerenone. Without a clear incremental outcome benefit, apabetalone would likely face restrictive reimbursement.

What generic launch risks exist for apabetalone?

There is no immediate generic launch risk because apabetalone has not been approved. The future risk profile would depend on the development strategy.

If approved through a broad cardiovascular indication

Generic manufacturers could challenge Orange Book patents through Paragraph IV certifications. Broad method-of-use claims would be vulnerable to arguments involving obviousness, written description, enablement, and lack of demonstrated clinical effect.

If approved through a CKD or heart-failure indication

Later, narrower patents could offer stronger commercial protection if they cover a specific patient population, endpoint, dosing regimen, or combination. However, skinny-label generic entry could permit use for unprotected indications while avoiding an actively patented use.

Manufacturing barriers

Manufacturing complexity may provide operational protection, but it is unlikely to block a technically capable generic manufacturer indefinitely. The principal barriers are likely clinical validation, regulatory approval, and market access rather than active pharmaceutical ingredient synthesis.

What patent litigation and settlement agreements affect apabetalone?

No major public Paragraph IV litigation or generic settlement agreement affects apabetalone because there is no approved reference product and no Orange Book listing.

The key legal risk is prospective. If Resverlogix or a commercial partner obtains approval, patent disputes could focus on:

  • Validity of early BET inhibitor composition claims
  • Scope of method-of-use claims
  • Obviousness of using apabetalone in CKD or heart failure
  • Written-description support for biomarker-defined populations
  • Infringement by generic labeling
  • Patent-term adjustment and patent-term extension calculations

How does apabetalone compare with competing cardiorenal drugs?

Product class Primary mechanism Regulatory position Competitive effect on apabetalone
Apabetalone BET transcriptional inhibition Investigational Requires new clinical validation
SGLT2 inhibitors Renal glucose transport inhibition Approved Strong cardiorenal outcome evidence
Finerenone Nonsteroidal mineralocorticoid receptor antagonism Approved Direct diabetic CKD competitor
GLP-1 receptor agonists Incretin pathway modulation Approved Expanding cardiovascular and metabolic use
PCSK9 inhibitors LDL receptor preservation Approved Strong lipid-lowering evidence
Colchicine Anti-inflammatory Approved for selected cardiovascular uses Competes in residual inflammatory risk

Apabetalone’s differentiation is mechanistic. Its disadvantage is the absence of a successful pivotal outcome trial.

Key Takeaways

  • Apabetalone is an investigational oral BET inhibitor developed by Resverlogix.
  • BETonMACE, the pivotal Phase 3 cardiovascular study, failed its primary MACE endpoint.
  • No FDA, EMA, or Health Canada approval exists.
  • Apabetalone has no Orange Book listing, NCE exclusivity, or immediate Paragraph IV threat.
  • CKD and heart failure represent the strongest remaining clinical opportunities.
  • The reported Hepalink Greater China license provides a potential regional development route.
  • The patent estate may retain value through composition, method-of-use, formulation, and biomarker claims, but early patent-term erosion is a material issue.
  • The base-case market projection is zero near-term product revenue.
  • An approved CKD or heart-failure indication could support a niche product with annual sales in the low hundreds of millions of dollars, subject to a successful new Phase 3 program and demonstrated benefit over existing cardiorenal therapies.

FAQs About Apabetalone Development and Commercial Potential

Is apabetalone approved for chronic kidney disease?

No. Apabetalone has not received FDA or other major-market approval for CKD, heart failure, cardiovascular disease, or any other indication.

Did apabetalone fail clinical trials?

The pivotal BETonMACE Phase 3 study failed to achieve statistical significance for its primary MACE endpoint. Secondary heart-failure and renal findings remain potential bases for further research.

Can a generic company launch apabetalone now?

No. There is no approved reference product, no FDA ANDA pathway based on an Orange Book-listed product, and no current generic launch opportunity.

Does apabetalone have biosimilar competition?

No. Apabetalone is a small molecule. Biosimilar regulation applies to biological products, not to apabetalone.

What would make apabetalone commercially viable?

A successful, narrowly targeted Phase 3 trial showing clinically meaningful renal or heart-failure benefit on top of standard therapy would be required. A broad cardiovascular claim is less likely to be commercially viable after the BETonMACE result.

References

  1. ClinicalTrials.gov. (n.d.). BETonMACE: BET inhibitor apabetalone in patients with diabetes and a recent acute coronary syndrome. U.S. National Library of Medicine.
  2. Nicholls, S. J., Ray, K. K., Johansson, J. O., Gordon, A., Sweeney, M., Halliday, C., Wolski, K., Ruotolo, G., Hovingh, G. K., Schwartz, G. G., et al. (2021). Selective BET bromodomain inhibition with apabetalone and cardiovascular events in patients with acute coronary syndrome and diabetes: The BETonMACE randomized controlled trial. Journal of the American College of Cardiology, 77(3), 296-306.
  3. Resverlogix Corp. (2018). Resverlogix announces licensing agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. Company press release.
  4. Resverlogix Corp. (2023). Annual report and management discussion and analysis.
  5. U.S. Food and Drug Administration. (n.d.). Breakthrough Therapy designation. FDA.
  6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
  7. Resverlogix Corp. (n.d.). Apabetalone development program and clinical data. Corporate development materials.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.